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STUDY PROTOCOL Open Access
The clinical effect of arrhythmia monitoring
after myocardial infarction (BIO-
GUARD|MI):study protocol for a randomized
controlled trial
Christian Jons1*, Peter Sogaard2, Steffen Behrens3, Jürgen Schrader4 , Sascha Mrosk4 and
Poul Erik Bloch Thomsen2
Abstract
Background: The increasing use of implantable cardiac monitors (ICMs) allows early documentation of
asymptomatic cardiac arrhythmias that would previously have gone unnoticed. The addition of remote monitoring
to cardiac devices means that physicians receive an early warning in cases of new-onset arrhythmias. While remote
monitoring has been suggested to increase survival in heart failure patients with implantable defibrillators, trials
using ICMs for continuous electrocardiographic monitoring of cardiac arrhythmias in the postmyocardial infarction
setting have shown that patients who experienced cardiac arrhythmias such as atrial fibrillation, bradycardia, and
ventricular tachyarrhythmia have an increased risk of major adverse cardiac events.
Methods: The Biomonitoring in patients with preserved left ventricular function after diagnosed myocardial
infarction (BIO-GUARD-MI) study is designed to investigate and clarify whether the incidence of major adverse
cardiac events can be decreased by early detection and treatment of cardiac arrhythmias using an ICM in patients
after myocardial infarction. In addition, the study will allow us to describe the interplay between baseline
characteristics, arrhythmias, and clinical events to improve the treatment of this high-risk patient population. The
study will enroll and randomize a cohort of high-risk postmyocardial infarction patients with CHA2DS2-VASc score ≥
4 and left ventricular ejection fraction > 35% to an ICM or conventional treatment. Physicians are provided with
suggestions on how to respond to ICM-documented arrhythmias. An estimated 1400 patients will be enrolled and
followed until 372 primary endpoints have occurred. In this paper, we describe the literature and rationale behind
the design and interventions towards new-onset arrhythmias, as well as future perspectives and limitations for the
use of ICMs.
Discussion: Remote monitoring may improve clinical outcome if it uncovers conditions with low symptom burden
which cause or indicate an increased risk. A simple and easily implementable response to the information is
important. Cardiac arrhythmias frequently start as asymptomatic, shorter lasting, and nightly events. The BIO-
GUARD-MI trial represents the first attempt to simplify the response to the rather complex nature of heart
arrhythmias.
Trial registration: Clinical Trials, NCT02341534. Registered on 19 January 2015.
Keywords: Implantable cardiac monitor, Cardiac arrhythmia, Myocardial infarction, Major adverse cardiac event,
CHADS-VASC score
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Background and rationale
Even though the prognosis after myocardial infarction
(MI) has improved much over recent decades due to im-
proved and faster revascularization, platelet inhibition,
and device therapy [1, 2], a proportion of postacute MI
(AMI) patients with additional risk factors remain at
high risk, with 5-year mortality ranging from 15% to
45% depending on the population [3–5]. The major issue
for future research in this population is to establish risk
factors that identify patients remaining at high risk and
in whom major adverse cardiac events (MACEs) can be
prevented [6]. Clinical risk factors remain important and
perform well but, as reviewed below, it is evident that
discrimination can get better.
Data from the observational Cardiac arrhythmias and
risk stratification after myocardial infarction (CARISMA)
study showed that incident arrhythmias detected by an
implantable cardiac monitor (ICM) in post-MI patients
were more predictive for MACE than a large number of
known demographical, clinical, and diagnostic risk pa-
rameters [7–10]. Due to the observational design of that
study, it was not possible to deduct from the results
whether diagnosing and treating the arrhythmias would
improve the clinical course of the patients. Conse-
quently, the Biomonitoring in patients with preserved
left ventricular function after diagnosed myocardial in-
farction (BIO-GUARD-MI) study has been designed to
answer this question.
Risk stratification using conventional clinical risk factors:
role of the CHADS-VASC score for risk stratification
beyond LEVF
Left ventricular ejection fraction (LVEF) has come to
play a dominant role in triaging patients towards high-
risk or low-risk regimes. If LVEF is 35% or less, patients
are implanted with an implantable cardioverter-defibril-
lator (ICD) due to the high risk of malignant arrhyth-
mias. After ICD implantation, patients are not only
followed with regular in-clinic controls, they are also
continuously monitored by remote monitoring (RM) sys-
tems through the ICD. Therefore, beyond an improved
prognosis by preventing sudden cardiac death, these pa-
tients may additionally benefit from RM through a de-
creased risk for hospitalization and death [11, 12].
In contrast, patients with relatively preserved left ven-
tricular function are considered at low risk, and current
treatment includes 1 year of dual antithrombotic ther-
apy, after which only acetylic salicylic acid, beta blockers,
and statins are continued, and the patients are followed
in general practice. While their risk is certainly lower,
this large difference in treatment and patient follow-up
is not justified by the prognosis in these groups [13–15].
In a recent study including 1500 unselected consecu-
tive patients with MI, only 20% of patients had an
LVEF ≤ 40% [16]. The incidence of cardiovascular
deaths or hospitalizations due to heart failure was 6%
at 30 months, with 56% of these events occurring in
patients with preserved LVEF. Hence, most events
occur in the group of patients with relatively pre-
served ejection fraction but with other risk factors.
Multiple investigational noninvasive risk parameters
have been developed and shown to stratify the risk in
postinfarction patients beyond LVEF. These include sig-
nal-averaged electrocardiography (ECG) [17], T-wave
alternans [18], and Holter parameters of baro-reflex sen-
sitivity [19] and heart rate variability [20]. These parame-
ters are not used clinically, mainly because no clinical
benefit of any treatment has been shown for patients
with these risk markers. Furthermore, they generally pre-
dict nonsudden (rather than sudden) death and the clin-
ical response is not trivial [6]. In addition, the diagnostic
risk markers derived from Holter monitoring, signal av-
eraged ECG, T-wave alternans, or programmed stimula-
tion study did not stratify the risk beyond clinical risk
parameters [8].
The clinical prediction rules for estimating risk of
stroke in patients with atrial fibrillation (the older
CHADS2 score and the newer CHA2DS2-VASc score)
were designed to estimate the risk of stroke in patients
with atrial fibrillation. However, these scores contain the
most important cardiovascular clinical risk factors and it
is not surprising that there is a strong association be-
tween increasing scores and the risk of clinical arrhyth-
mias as well as MACEs [21–25].
Risk stratification and arrhythmia management using
implantable devices
Recently, large randomized trials have shown that long-
term monitoring of cardiac arrhythmias using RM in pa-
tients with cardiac devices may improve clinical outcome.
The Implant-based multiparameter telemonitoring of pa-
tients with heart failure (IN-TIME) trial randomized 664
patients with ICDs or cardiac resynchronization therapy
defibrillators (CRT-Ds) to RM or conventional in-clinic
monitoring. There was a 30% reduction in the composite
clinical (‘Packer’) score and a statistically significant reduc-
tion in all-cause mortality [11]. The majority of clinical
alerts triggering reaction were arrhythmias, but the data
collected did not allow for a precise correlation between
physicians’ responses and outcome.
The Effectiveness and cost of ICD follow-up schedule
with telecardiology (ECOST) trial of 433 ICD patients
randomized to RM or no RM did not show an improve-
ment in the rate of MACEs. However, a recent patient-
level re-analysis found that RM reduced the endpoint of
death or hospitalization for heart failure (combined haz-
ard ratio at 12 months, 0.64; P = 0.007) in pooled data
Jons et al. Trials          (2019) 20:563 Page 2 of 11
from the IN-TIME and ECOST trials [12], with both tri-
als showing similar effect sizes.
In parallel, the Remote management of heart failure
using implantable electronic devices (REM-HF) trial, a
study of 1650 patients with ICD and CRT devices ran-
domized to weekly RM transmissions or no RM, did not
find an effect on the primary endpoint of all-cause death
or cardiovascular hospitalization (hazard ratio, 1.01; P =
0.87) [26]. The differences in outcome between IN-
TIME and ECOST on one side and REM-HF on the
other can be plausibly attributed to differences in trans-
mission rate (daily versus weekly) and other details in
the study design [27].
In the observational CARISMA trial, 300 patients with
an AMI and an LVEF < 40% were implanted with an
ICM [7]. The study showed that arrhythmias docu-
mented on the ICM preceded 70% of MACEs, and car-
diac arrhythmia was the most powerful predictor for a
MACE. In fact, an unexpectedly high incidence of new-
onset atrial fibrillation, second- or third-degree atrioven-
tricular block, sinus bradycardia, ventricular tachycardia,
and ventricular fibrillation were diagnosed by the ICM
during the study. Almost 90% of these arrhythmias were
asymptomatic, short lasting, and occurred at night, and
hence would probably go undetected without the im-
planted ICM. Further investigation and treatment of
these arrhythmias were, however, not part of the proto-
col, and whether intervention and treatment of ICM-
documented arrhythmias could have changed the out-
come remains unanswered.
The BIO-GUARD-MI study population selection cri-
teria are based on these observations. The study enrolls
patients with an LVEF > 35%. Little is known about the
incidence of arrhythmia and the correlation to clinical
outcome in this population, and the BIO-GUARD-MI
study is therefore designed to investigate not only the in-
cidence of arrhythmias according to different risk pro-
files, but also how arrhythmias are associated with major
clinical events and whether management of these ar-
rhythmias according to current guidelines influences the
clinical course of the patients.
Study objectives
The primary objective of the BIO-GUARD-MI study is
to investigate whether the early diagnosis of cardiac ar-
rhythmias provided by an ICM with automated daily
RM and the consequent medical treatment will decrease
the risk of MACEs in patients with previous AMI, LVEF
> 35%, and a CHA2DS2-VASc risk score ≥ 4/5 (men/
women). The study is powered to show a relative reduc-
tion of 25%.
Secondary objectives include the time to diagnosis of
arrhythmias, each MACE component evaluated individu-
ally, the influence of each component of the CHA2DS2-
VASc score on MACEs, and quality of life. Exploratory
analyses will address the following interactions: 1) ar-
rhythmias and clinical endpoints; 2) baseline conditions
and clinical endpoints; 3) baseline conditions and ar-
rhythmias; and 4) treatments and clinical endpoints.
Study design
The BIO-GUARD-MI study is a multicenter, open, pro-
spective, randomized controlled international study with
an event-driven design. The investigational sites are hos-
pitals with facilities for the treatment of AMI and ex-
perience in device treatment of arrhythmias. High-risk
patients with recent or chronic MI are invited to partici-
pate. A flow diagram of the study is shown in Fig. 1. A
spirit checklist can be found online (Additional file 1).
Patients who fulfill the enrollment criteria may be en-
rolled after conclusion of treatment for an AMI (if an
ICD indication was excluded by a confirmed LVEF >
35%) or if they had a chronic MI. Investigators invite
them to participate and collect written informed con-
sent. Patients are randomized in a 1:1 ratio to receive
implantation of an ICM or conventional treatment. The
investigator receives the randomized allocation from a
concealed computer-generated sequence stratified for
the investigational site and ST-elevation MI (STEMI)/
non-STEMI (NSTEMI) after enrollment. Both investiga-
tor and patient are aware of the randomization result.
All patients are discharged to the typical post-MI follow-
up. Neither ICM nor control group patients are sched-
uled to return to the implanting site for regular follow-
up visits.
To assess the primary endpoint, all patients will re-
ceive telephone calls every 6 months from an independ-
ent Clinical Research Organization. If they report that
they have been hospitalized, the investigational site is
notified and reports the adverse event based on docu-
mentation requested from the relevant hospital. The
telephone calls will be conducted in a way so as not to
interfere in the normal healthcare (i.e., the patient will
receive no medical advice of any kind but will only be
asked about events of the preceding period) (see also
Fig. 2).
This study complies with the declaration of Helsinki
and with ISO 14155. It is registered at clinicaltrials.gov
(NCT02341534).
Inclusion and exclusion criteria
Patient inclusion and exclusion criteria are presented in
Table 1. Changes were made to the enrollment criteria
in that a limitation to enrollment within 21 days of an
AMI was removed to increase the eligible population
and to also describe the incidence of arrhythmias very
late after the MI. Furthermore, the CHADS2 score used
in the initial protocol was later substituted with the
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CHA2DS2-VASc score which took over the role of
CHADS2 in cardiovascular guidelines and clinical
practice.
The implantable cardiac monitor
The BioMonitor 2 (Biotronik SE & Co. KG, Berlin,
Germany) or successor devices will be used [28]. It is a
subcutaneous ICM that continuously monitors the heart
rhythm. It automatically records a subcutaneous ECG
(sECG) when triggered according to certain criteria, as
shown in Table 2. The expected service time is 4 years; if
a device battery expires during the study, it will be re-
placed. The device automatically transmits once per day
up to six uncompressed full-length sECG snapshots to
the Home Monitoring Service Center via Biotronik
Home Monitoring® [29]. The physician can assess the
message content on a secure website.
Arrhythmia diagnosis, documentation, and response
The BIO-GUARD-MI study has been designed to track
and document the time-wise response of the investiga-
tors to arrhythmia events. A large effort has been made
Fig. 1 BIO-GUARD-MI flow diagram. AV atrioventricular, CEMB central electrocardiogram monitoring board, ICD implantable cardioverter-
defibrillator, ICM implantable cardiac monitor, TIA transient ischemic attack, VF ventricular fibrillation, VT ventricular tachycardia
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to ensure that current guidelines are followed where ap-
propriate. In some instances the guidelines do not pro-
vide precise recommendations and, in these cases,
recommendations have been based on previous literature
and observations from the CARISMA study. Recom-
mended responses to detected arrhythmias and the ra-
tionale and literature behind the responses are provided
in Table 2.
Central electrocardiogram monitoring board
The central electrocardiogram monitoring board (CEMB)
receives alerting e-mails from the Home Monitoring Ser-
vice Center and reviews all sECGs. It discards detections of
noise or artifacts, and if any events fulfill predefined criteria
the responsible physician is notified by e-mail. At the same
time, the CEMB enters the event in the study database to
ensure correct recording of the event, including the precise
time of the sECG transmission to allow the evaluation of
the time to the investigator’s reaction. The CEMB also pro-
vides a centralized follow-up on the investigator’s assess-
ment, who is responsible for checking and adjudicating on
the arrhythmias immediately but at the latest within 7 days
after receiving an arrhythmia notice from the CEMB. How-
ever, the CEMB does not support ECG interpretation or
medical decisions for study participants.
Endpoints
The primary endpoint is the time from randomization to
the first MACE during the clinical investigation. MACEs
Fig. 2 SPIRIT figure. ICM implantable cardiac monitor
Table 1 Inclusion and exclusion criteria
Inclusion criteria
History of MI according to guidelines:
CHA2DS2-VASc score≥ 4 in men/≥ 5 in women
LVEF > 35% as estimated within 6 months before enrollment but
after conclusion of acute MI treatment
Patient accepts activation of home monitoring
Patient has provided written informed consent
Exclusion criteria
Platelet count < 90,000 per mm3 or patients with hemorrhagic
diathesis
Permanent oral anticoagulation treatment for atrial fibrillation
Indication for chronic renal dialysis
Pacemaker or ICD implanted or indication for implantation
Parkinson’s disease
Life expectancy < 1 year
Participation in another interventional clinical investigation during the
course of the study, i.e. the participation in a noninterventional
clinical investigation is allowed.
Age < 18 years
Woman who are pregnant or breast feeding
ICD implantable cardioverter-defibrillator, LVEF left ventricular ejection fraction,
MI myocardial infarction
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Table 2 Recommended responses to detected arrhythmias, the rationale, and literature behind the rationale
Arrhythmia Definition according to ICM
programming
Recommended investigations and
treatments
Rationale
First incidence or
sudden
progression in
burden of any
arrhythmia
ECG to evaluate QRS width and other
intervals, ischemia, etc. Echocardiography
to exclude progressive HF or valve disease.
Consider coronary angiogram if symptoms
exceed or cannot be explained by
arrhythmia severity
BIO-GUARD-MI is based on data from the
CARISMA trial [7]. In that study, any
arrhythmia including sinus bradycardia, AV
block, AF, nonsustained VT, and sustained
VT/VF was associated with an increased
risk of any endpoint including re-
infarction, stroke, progressive HF and
death. Hence, we recommend that any
patient be evaluated for progressive HF or
recurrence of symptomatic ischemic heart
disease
AF or atrial flutter
< 5.5 h
RR variability > 12.5% or detected as
HVR (> 160 bpm for 8 cycles) for > 6
min, but lasting < 5.5 h total/24 h
(includes bigeminy rejection)
Beta blocker In a large registry-based analysis, beta
blockers were associated with a better
prognosis in patients with AF [30], after
cardiac surgery [31] and renal disease [32].
In comparison, calcium antagonists may
be equally efficient for symptom relief and
rate control [33], but there is currently a
paucity of knowledge for best medicinal
rate control methods [34]. Based on this
rationale, beta blockade is the
recommended primary medication for
MACE prevention and for rate control in
new-onset paroxysmal AF in this
population
Initiation of anticoagulation therapy
according to patient profile and wishes
Current consensus on device-detected AF
states that anticoagulation can be
considered but does not necessarily need
to be initiated in high-risk patients if daily
episodes last < 5.5 h/day [35]. All patients
in the BIO-GUARD-MI study have a
CHA2DS2-VASc score indicating a high
stroke risk
AF or atrial flutter
> 5.5 h
RR variability > 12.5% or detected as
HVR (> 160 bpm for 8 cycles) > 5.5 h
total/24 h (includes bigeminy rejection)
Initiate anticoagulation therapy Current guidelines recommend initiation
of anticoagulation treatment if the total
duration of daily episodes of AF exceeds
5.5 h/day [35].
DC cardioversion if appropriate. Plan for
rhythm and/or frequency management
strategy. Rhythm management strategy is
encouraged unless there are
contraindications to this, or the patient is
unwilling. Radiofrequency ablation is
preferred over drug treatment as long-
term rhythm management
Even though rate control is not inferior to
rhythm control, there is an advantage if
sinus rhythm can easily be restored [8]. In
a large Cochrane-based review, there
seems to be a slightly higher mortality
when choosing a rhythm control [36], but
this seems to be due to the use of
antiarrhythmic drugs, whereas catheter
ablation is consistently associated with an
improved outcome in high-risk patients
[37, 38]
Optimize antihypertensive treatment Antihypertensive treatment has been
repeatedly shown to lower the incidence
of AF [39], and controlling systolic blood
pressure over time seems to be key [40].
Bradycardia < 40 bpm for ≥ 10 s If < 40 bpm and symptomatic, or < 30 bpm
regardless of symptoms, patient should be
evaluated for optimization of medical
treatment and pacemaker therapy
Even though based on sparse literature,
current guidelines do not recommend
pacemaker implantation in asymptomatic
sinus bradycardia [41]. In the CARISMA
trial, sinus bradycardia was associated with
an adverse outcome, mainly due to an
association with progressive HF [7]. Hence,
we recommend thorough evaluation of
symptoms, heart function, and coronary
circulation in progressive sinus
bradycardia, particularly with heart rate <
30 bpm. There are currently no
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comprise the following events: 1) cardiovascular death;
2) worsening of the status of the patient due to heart
failure, requiring acute unscheduled hospitalization or
urgent visit; or 3) unscheduled cardiovascular
hospitalization due to arrhythmia, acute coronary syn-
drome, stroke, major bleeding, or systemic embolism.
This broad definition of the primary endpoint was chosen
due to the basic assumption that all the items are increased
in post-MI patients and that acute arrhythmias can be pre-
dictive for all of them. Therefore, treatment of the patients
after acute arrhythmias may improve any of the items.
Hospitalization that result from events detected in the ICM
are by definition scheduled and are not counted as
endpoints. Major bleeding was included to capture possible
side effects of anticoagulation treatment after detection of
AF.
Subgroups are predefined according to the following
characteristics at enrollment for exploratory analyses
with respect to the occurrence of the predefined ar-
rhythmias, the primary endpoint, and other predefined
outcomes: 1) all individual CHA2DS2-VASc-score com-
ponents; 2) men versus women; 3) CHA2DS2-VASc-
score (≤ 4 in men/≤5 in women versus ≥5 in men/≥6
in women); 4) age (< versus ≥ median); 5) LVEF (< ver-
sus ≥ median); 6) body mass index (underweight or
normal or overweight versus obese, cut-off 30 kg/m2);
Table 2 Recommended responses to detected arrhythmias, the rationale, and literature behind the rationale (Continued)
Arrhythmia Definition according to ICM
programming
Recommended investigations and
treatments
Rationale
randomized or larger observational trials to
support management of these events
Sinus arrest Pause lasting > 3 s For asymptomatic pauses > 6 s or
symptomatic pauses > 3 s, adjust medicine
accordingly and evaluate for pacemaker
therapy
Even though such pauses are considered
benign and not associated with an
adverse outcome, pacemaker implantation
can be considered for prevention of
syncope [41]. Sinus arrest was not
associated with an adverse outcome in
CARISMA [7]
AV block type 2 or
3
< 40 bpm for ≥ 10 s or pause > 3 s Pacemaker implantation for high-degree
AV block persisting after AV nodal slowing
medications.
For patients with AV block, there is class I
indication for pacemaker implantation
regardless of symptom/arrhythmia
correlation [41]
If LVEF ≤ 40% a CRT-P is recommended in
patients with an expected right ventricular
pacing burden > 50%
Studies have shown that biventricular
pacing in patients with symptomatic HF
and high ventricular pacing burden can
prevent HF events compared with right
ventricular pacing. The precise indications
in terms of ejection fraction and pacing
burden are not specified in current
guidelines. For the purpose of the present
study, we consider the specified cut-offs
reasonable
Nonsustained VT HVR > 160 bpm for 8 cycles If LVEF ≤ 35%, EPS (MADIT-I) is
recommended
An EPS has been shown to identify high-
risk patients with previous myocardial
infarction that will benefit from an ICD
because of high risk of malignant
arrhythmias [42, 43]
If symptomatic after beta blocker
treatment, radiofrequency ablation is
recommended
Multiple studies have shown that
radiofrequency ablation effectively treats
ventricular ectopy and tachycardia [44].
While an effect on mortality has never
been proved, ablation in patients with
ventricular burden > 20% may restore left
ventricular function in the setting of HF
[45]
Sustained VT or VF HVR > 160 bpm for 8 cycles Implantation of ICD or CRT-D.
Radiofrequency ablation is preferred over
drug treatment as long-term rhythm
management
Sustained VT > 30 s or VF gives indication
for an ICD according to guidelines [42, 46].
If ECG has QRS > 150ms or observations
on the ICM indicates risk of high right
ventricular pacing percentage (> 40%), a
CRT-D device should be implanted [41]
AF atrial fibrillation, AV atrioventricular, CRT-D cardiac resynchronization therapy defibrillator, CRT-P cardiac resynchronization therapy pacemaker, DC direct
current, ECG electrocardiogram, EPS electrophysiological study, HF heart failure, HVR high ventricular rate, ICD implantable cardioverter-defibrillator, ICM
implantable cardiac monitor, LVEF left ventricular ejection fraction, MACE major adverse cardiac event, RR cycle length, VF ventricular fibrillation, VT
ventricular tachycardia
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7) history of atrial fibrillation (yes versus no); 8)
NSTEMI versus STEMI; 9) ‘early’ (within 40 days of
most recent AMI) versus ‘late’ enrollment; and 10) his-
tory or presence of kidney failure (yes versus no).
Boards and committees
A Data Safety Monitoring Board (DSMB) will regularly
review accumulating study data to address patient safety
and ethical issues of the study. The DSMB will perform
the two interim analyses and the final analysis of the pri-
mary endpoint. Based on the interim data, the DSMB
will give the request to stop the clinical investigation for
superiority or give a recommendation to the steering
committee and the sponsor whether to continue the
clinical investigation as planned, to adapt the sample
size, or to stop the clinical investigation for safety rea-
sons or for futility.
The blinded Endpoint and Adverse Event Committee
will analyze adverse events with respect to the specified
endpoint criteria and will adjudicate if a primary or sec-
ondary endpoint has been met.
Members of both bodies cannot participate in the
study as investigators.
Data collection
Data will be entered into a password-protected internet-
based Clinical Data Management System purposely de-
signed by the sponsor and hosted by MedNet Solutions
(MN, USA). Data will be monitored by trained em-
ployees of the sponsor or subcontracted CROs.
Statistical design and analysis
The primary hypothesis will be tested with the Kaplan–
Meier method by a log-rank test stratified for STEMI/
NSTEMI after enrollment. All analyses will be con-
ducted according to the intention-to-treat principle. Pa-
tients who exit the study prematurely will be included in
the analysis until their exit. Details will be defined in a
statistical analysis plan.
The study is designed to allow for early discontinu-
ation in case of superiority or futility and to adapt the
sample size in case of positive results but insufficient
power to meet the statistical significance with the ini-
tially planned sample size. The study is designed as a
three-stage adaptive group sequential test procedure ac-
cording to O’Brian Fleming with survival endpoint.
Survival-analysis techniques (Kaplan–Meier, log-rank
test, Cox regression, hazard ratio and confidence inter-
val) will be used to compare the incidence of all survival
data endpoints between the groups. Interaction with
subgroup variables and other covariates will also be ana-
lyzed by a Cox proportional-hazards model. For two-
sided and one-sided statistical tests, P values < 0.05
and < 0.025 will be considered statistically significant,
respectively. No adjustments for multiplicity will be
undertaken, and all findings based on prespecified hy-
potheses as well as post-hoc analyses such as multivari-
ate analyses will express only supportive evidence for the
primary hypothesis. Statistical testing will be conducted
with SAS software, version 9.4 or later (SAS Institute).
Sample size
It is expected that the risk of a first MACE at 1 year is
reduced by 25% in the ICM group compared with the
control group. A one-sided log-rank test is performed in
the context of a confirmatory analysis of the primary hy-
pothesis at every interim analysis and the final analysis.
A total of 372 patients with events are needed to main-
tain the overall 2.5% significance level. The interim ana-
lyses and the final analysis will be conducted with 124,
248, and 372 patients with at least one MACE during
the clinical investigation, respectively. The statistical
power of the final analysis is 80%. A drop-out of 5% of
patients per year is expected.
The total number of patients who will be included will
depend on the observed endpoint rate and on enroll-
ment speed, since the first enrolled patients are followed
for a longer period if enrollment is slower. Current esti-
mates indicate that up to 1400 patients will be enrolled.
Risk of bias
Blinding would have been possible if control patients re-
ceived an inactivated ICM. The decision against this op-
tion was based on both the invasiveness of the ICM
implantation and the possibility that general practi-
tioners (GPs) or local cardiologists might treat patients
with an ICM (as they do not know it is inactive) differ-
ently than they would standard post-MI patients.
Thus, the risk of bias was reduced by other measures.
All unnecessary contacts between patients in the ICM
group and the investigational site are avoided by the
study design, so that a preferential treatment of patients
by investigators is unlikely. Patients are followed by GPs
or local cardiologists (as per regional routine) and do
not return to the investigational site except for the treat-
ment of arrhythmias. GPs are asked to send the study
patients of both groups to the investigational site for
treatment of arrhythmias that are recorded convention-
ally if tertiary level care is required. Furthermore, be-
cause the RM system is known to be very reliable,
patients are only contacted by the investigational sites
for rare long-lasting transmission gaps (> 40 days) [29].
Discussion
There is little doubt that using implantable monitors to
continuously monitor biological functions will increase
in the future and to some extent reduce the need for in-
clinic controls. However, several open questions remain,
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including what to monitor and how frequent and how
sensitive the monitoring should be.
While tailored patient management guided by RM has
been tested in many groups of patients, the focus has
been driven by the availability of technology and has
concentrated on patients with diabetes, chronic ob-
structive pulmonary disease (COPD), chronic heart fail-
ure, and hypertension. A search on ClinicalTrials.gov
shows that most trials investigating telemedicine to a
large extent still involve these patient groups. Hence, at
least in the near future, heart and pulmonary function,
blood pressure, and simple metabolic measures seem to
dominate telemedicine.
RM results in better treatment control in patients with
diabetes [47] and hypertension [48], whereas this effect
has been more difficult to prove in patients with COPD
[49]. A rationalistic interpretation could be that moni-
toring is more promising in conditions that present with
little or no symptoms, such as hyperglycemia and high
blood pressure, whereas COPD exacerbations present
quite acutely. Another key element for successful RM
seems to be a simple and easily implementable response
to the information obtained by RM. The recent Cardio-
MEMS heart sensor allows monitoring of pressure to
improve outcomes in NYHA class III heart failure pa-
tients (CHAMPION) trial involved continuous measure-
ment of the pulmonary wedge pressure. The response
was a simple, predefined titration scheme for guideline-
recommended heart failure medication dosage which re-
sulted in a significant decrease in hospitalizations due to
heart failure [46, 50]. In contrast, some larger trials in-
volving monitoring of multiple biological measures have
shown neutral results [51, 52], while modifications in de-
sign can make a difference [53].
ICMs have decreased in size and improved in their sig-
nal quality. Their sensitivity for detecting brady arrhyth-
mias and ventricular high-rate episodes is very good, but
specificity is limited due to undersensing and noise. For
this reason, the CEMB was instituted to filter these epi-
sodes. The sensitivity for shorter regular episodes of
atrial fibrillation is lower, but it is unlikely that the de-
vice will miss longer lasting (e.g., hours to days) episodes
of atrial fibrillation. Hence, the sensitivity to identify pa-
tients with arrhythmias is very good [28]. Due to their
subcutaneous positioning, they cause a very low risk, and
they do not limit the patient’s activities. Remote monitor-
ing of cardiac implants, especially ICDs, has been estab-
lished for a long time, is well accepted by the majority of
patients, and is state of the art in ICMs these days.
Cardiac arrhythmias frequently start as asymptomatic,
shorter lasting, and nightly events [7], and hence seem
to be well suited for RM. The downside is that, since
cardiac arrhythmias are linked to an increased risk of
multiple outcomes, a response is not always simple and
straightforward. The BIO-GUARD-MI trial represents
the first attempt to simplify the response to the rather
complex nature of cardiac arrhythmias and, if successful,
we believe the trial can significantly advance the field of
clinical telemedicine and contribute to improved patient
care and prevention of hospitalization.
Trial status
The trial is currently recruiting. The patient recruitment
phase started in August 2015 and is expected to end in
August 2021. The current protocol version is 4.0, 28 April
2017. All amendments were submitted to the ethics com-
mittees and, if changes were significant, were approved by
them. All investigators were trained on the amendments.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (PDF 42 kb)
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